Randi M L, Barbone E, Fabris F, Varotto L, Macri C, Girolami A
Institute of Medical Semeiotics, IVth Chair of Internal Medicine, University of Padua Medical School, Italy.
J Med. 1994;25(6):363-9.
The common origin of myeloproliferative disorders can explain the possible evolution of polycythemia vera to post-polycythemia myeloid metaplasia (PPMM). Such a possible event is usually considered linked to the use of myelosuppressive agents in particular 32P. Occasionally, myelofibrosis following essential thrombocythemia has also been described. We report here 19 cases of post-polycythemia myeloid metaplasia out of 214 polycythemia vera patients (8.8%). The majority of these patients received 32P therapy. However, busulfan also seems to have some role in the modification of polycythemia vera. In particular, the association of more than one myelosuppressive agent may favour the evolution of PPMM.
骨髓增殖性疾病的共同起源可以解释真性红细胞增多症向真性红细胞增多症后骨髓化生（PPMM）可能的演变。这样一种可能的情况通常被认为与使用骨髓抑制药物特别是32P有关。偶尔，也有关于原发性血小板增多症后骨髓纤维化的描述。我们在此报告214例真性红细胞增多症患者中有19例发生了真性红细胞增多症后骨髓化生（8.8%）。这些患者大多数接受了32P治疗。然而，白消安似乎在真性红细胞增多症的转变中也起了一定作用。特别是，不止一种骨髓抑制药物的联合使用可能会促进PPMM的演变。
